Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02024646 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 484
- Enrollment target
NCT02024646: Completed Phase 3 study, sponsored by Bausch Health Americas.
NCT02024646 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 484 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02024646, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 484 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.
Primary Outcome
ACR20 is used as a measurement of the proportion of subjects who are reaching a 20% improvement of tender an swollen joint counts. The higher percent of subjects reaching a higher improvement percentage shows greater success.
Interventions
- DRUG Placebo
- DRUG 210 mg brodalumab
- DRUG 140 mg brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
What the finished NCT02024646 record still lists
NCT02024646 is an interventional study that assigns participants to a tested intervention. The registered 484 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02024646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02024646 about?
NCT02024646 is a clinical study titled "Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis". The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety...
What is the current status of trial NCT02024646?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 484 participants. The study started on 2014-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02024646?
The interventions under investigation include: Placebo (DRUG), 210 mg brodalumab (DRUG), 140 mg brodalumab (DRUG).
Who is sponsoring clinical trial NCT02024646?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02024646's enrollment target sits among peer trials
484 791st of 2000 higher than 1,209 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT02871726 · 483 participants · NA
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia